Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 9

1.

BH3 response profiles from neuroblastoma mitochondria predict activity of small molecule Bcl-2 family antagonists.

Goldsmith KC, Lestini BJ, Gross M, Ip L, Bhumbla A, Zhang X, Zhao H, Liu X, Hogarty MD.

Cell Death Differ. 2010 May;17(5):872-82. doi: 10.1038/cdd.2009.171. Epub 2009 Nov 6.

2.

Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy.

Kang MH, Reynolds CP.

Clin Cancer Res. 2009 Feb 15;15(4):1126-32. doi: 10.1158/1078-0432.CCR-08-0144. Review.

3.

BH3 profiling--measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions.

Del Gaizo Moore V, Letai A.

Cancer Lett. 2013 May 28;332(2):202-5. doi: 10.1016/j.canlet.2011.12.021. Epub 2012 Jan 8. Review.

4.

BH3 mimetics: status of the field and new developments.

Billard C.

Mol Cancer Ther. 2013 Sep;12(9):1691-700. doi: 10.1158/1535-7163.MCT-13-0058. Epub 2013 Aug 23. Review.

5.

[Progress in small-molecule inhibitors of Bcl-2 family proteins].

Tang Y, Zhang DY, Wu XM.

Yao Xue Xue Bao. 2008 Jul;43(7):669-77. Review. Chinese.

PMID:
18819468
6.

Mimicking the BH3 domain to kill cancer cells.

Ni Chonghaile T, Letai A.

Oncogene. 2008 Dec;27 Suppl 1:S149-57. doi: 10.1038/onc.2009.52. Review.

7.

BH3 mimetics to improve cancer therapy; mechanisms and examples.

Zhang L, Ming L, Yu J.

Drug Resist Updat. 2007 Dec;10(6):207-17. Epub 2007 Oct 24. Review.

8.

New dimension in therapeutic targeting of BCL-2 family proteins.

Besbes S, Mirshahi M, Pocard M, Billard C.

Oncotarget. 2015 May 30;6(15):12862-71. Review.

9.

Polyphenols as mitochondria-targeted anticancer drugs.

Gorlach S, Fichna J, Lewandowska U.

Cancer Lett. 2015 Oct 1;366(2):141-9. doi: 10.1016/j.canlet.2015.07.004. Epub 2015 Jul 13. Review.

PMID:
26185003
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk